MedTrace Logo

Pegcetacoplan (APL-2) in Neovascular AMD

NCT03465709 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2020-09-16

Study results available
· View outcomes & findings →

Summary

Safety Assessment of Pegcetacoplan in Patients with Neovascular AMD

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

Pegcetacoplan

Study Drug

Sponsors & Collaborators

  • Apellis Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Federico Grossi, MD, PhD · Apellis Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-14
Primary Completion
2019-04-05
Completion
2019-04-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03465709 on ClinicalTrials.gov